Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InvionFRA:7C8 Pretax Margin % is % as of Dec. 2025. The stock has 2 warning signs investors should review. Among 961 Drug Manufacturers companies, Invion ranks worse than 104058.17% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Invion's Pre-Tax Income for the
six
months ended in Dec. 2025 was €-2.02 Mil. Invion's Revenue for the
six
months ended in Dec. 2025 was €0.00 Mil. Therefore, Invion's pretax margin for the quarter that ended in Dec. 2025 was %.
The historical rank and industry rank for Invion's Pretax Margin % or its related term are showing as below:
FRA:7C8's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.28 * Ranked among companies with meaningful Pretax Margin % only.
Invion (FRA:7C8) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Invion Pretax Margin % Related Terms
Invion Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Invion's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Invion's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invion Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Invion's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Invion's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invion (FRA:7C8) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Invion and its competitors. According to the industry distribution chart, Invion ranks #999999 out of 961 companies in the Drug Manufacturers industry.
Is Invion's Pretax Margin % too high?
Invion's current Pretax Margin % is %. Based on the distribution chart, Invion ranks #999999 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Invion's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Invion ranks #999999 out of 961 companies for Pretax Margin %. This places Invion in the lower half of its industry. The industry median Pretax Margin % is 7.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Invion and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invion's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Based on GuruFocus' analysis, Invion (FRA:7C8) is currently considered Possible Value Trap. The stock's GF Value™ is €0.08, compared to a current price of €0.02 — trading 73.8% below its estimated fair value. The current Pretax Margin % is %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Invion (FRA:7C8), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7C8 has been successfully added to your 
